| DC Field | Value | Language |
|---|
| dc.contributor.author | Щербинина, Марина | |
| dc.contributor.author | Гладун, Виктория | |
| dc.date.accessioned | 2019-06-14T08:15:53Z | |
| dc.date.available | 2019-06-14T08:15:53Z | |
| dc.date.issued | 2017 | |
| dc.identifier.citation | ЩЕРБИНИНА, Марина; ГЛАДУН, Виктория. Эффективность урсодезоксихолевой кислоты в терапии гастроэзофагеальной рефлюксной болезни. В: Sănătate Publică, Economie şi Management în Medicină. 2017, №. 4(74), сс. 70-73. ISSN 1729-8687. | en_US |
| dc.identifier.issn | 1729-8687 | |
| dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/1548 | |
| dc.identifier.uri | http://revistaspemm.md/wp-content/uploads/2020/05/Rvista_SPEMM_4-74-2017.pdf | |
| dc.description | Днипровский национальный университет
им. Олеся Гончара, Факультет медицинских
технологий диагностики и реабилитации,
г. Днипро, Украина | en_US |
| dc.description.abstract | Efficiency of ursodezoxycolic acid (UDCA) in the
therapy of gastroesophageal reflux disease (GERD)
Objective: to study the clinical efficacy of UDCA in
patients with GERD using the international questionnaire GerdQ.
Materials and methods. Patients with GERD for 6
weeks received therapy: 1st group (n = 44) pantoprazole 40 mg/day; 2nd group (n = 46) pantoprazole (40
mg/day) and UDCA (10 mg/kg/day). The results of the
questionnaire were evaluated before and at the end of
the observation period.
Results. The total score of questionnaires before treatment: 1st group 15 ± 4.37, 2nd group – 16 ± 4.96 (p>
0.05), in the category B, respectively, 4.45 ± 0.68 and
4.39 ± 0.64 (p> 0.05); after treatment: 1 st group, 14 ±
2,46, 2nd group 7 ± 2,21 (p <0,05), in the category B,
3,81 ± 0,61 and 1,31 ± 0,2 respectively (p <0.01).
Conclusions. Additional inclusion of UDCA in the
therapy scheme of GERD compared with monotherapy
with pantoprazole increases its effectiveness by 1.5
times. Reduction of the score of the questionnaire for
category B after treatment is evidence of the presence of
the biliary component in the pathogenesis of GERD. | en_US |
| dc.language.iso | ru | en_US |
| dc.publisher | Asociația Obștească "Economie, Management și Psihologie în Medicină" din Republica Moldova | en_US |
| dc.relation.ispartof | Sănătate Publică, Economie şi Management în Medicină: Conferința națională de gastroenterologie și hepatologie cu participare internaţională ”Actualități în gastroenterologie și hepatologie” cu tematica: Stările precanceroase și canceroase în patologia digestivă și cea hepatică, dedicată anului Nicolae Testemițanu 29 noiembrie 2017 Chișinău, Republica Moldova | |
| dc.subject | gastroesophageal refl ux disease | en_US |
| dc.subject | GerdQ questionnaire | en_US |
| dc.subject | ursodeoxycholic acid | en_US |
| dc.subject.ddc | УДК: 616.333–008.6–085–036.8:615.243.3 | |
| dc.subject.mesh | Esophagitis, Peptic--drug therapy | en_US |
| dc.subject.mesh | Gastroesophageal Reflux--drug therapy | en_US |
| dc.subject.mesh | Ursodeoxycholic Acid--therapeutic use | en_US |
| dc.subject.mesh | Data Interpretation, Statistical | en_US |
| dc.subject.mesh | Surveys and Questionnaires | en_US |
| dc.subject.mesh | Outcome Assessment (Health Care) | en_US |
| dc.title | Эффективность урсодезоксихолевой кислоты в терапии гастроэзофагеальной рефлюксной болезни | en_US |
| dc.title.alternative | Efficiency of ursodezoxycolic acid (UDCA) in the therapy of gastroesophageal reflux disease (GERD) | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | Sănătate Publică, Economie şi Management în Medicină Nr. 4 (74) / 2017
|
